ح
Holistic Health AI.AI
Editorial notes

When the science moves, we say so.

Medical evidence changes. A guide that was accurate a year ago can quietly go out of date. When something meaningful shifts, we publish a short editorial note explaining what changed, why it matters, and how Hakim responded.

June 18, 2026

Colchicine for cardiovascular prevention — a cautious re-read

What changed
The CLEAR SYNERGY (OASIS-9) trial (NEJM, 2024) tempered the earlier COLCOT and LoDoCo2 enthusiasm for low-dose colchicine after myocardial infarction.
Why it matters
For a while, colchicine looked like a straightforward add-on for post-MI inflammation. The signal now looks smaller and less certain than the early trials suggested.
How Hakim responded
We softened the language in the inflammation and heart guides from 'promising add-on therapy' to 'an active area of research; discuss with your cardiologist'.

Guides updated

May 2, 2026

Fibre and cardiovascular mortality — the case gets stronger

What changed
A 2024 umbrella review across 45 meta-analyses reaffirmed that every additional 8 g of dietary fibre is linked to a 5–10 % reduction in cardiovascular mortality.
Why it matters
Fibre remains one of the most consistent, boring, undramatic wins in nutrition. Worth restating clearly.
How Hakim responded
Upgraded the fibre and healthy-digestion guides' evidence tier from 'moderate' to 'strong' and added the umbrella review to their reference lists.

Guides updated

    March 14, 2026

    Melatonin doses — lower than most bottles suggest

    What changed
    Sleep-medicine reviews increasingly favour 0.3–1 mg melatonin over the 3–10 mg found in most supplement bottles, especially in older adults.
    Why it matters
    Higher doses do not work better and can leave people groggy the next morning.
    How Hakim responded
    Rewrote the melatonin note in the sleep guides to lead with the low-dose, physiologic-range recommendation and to name morning grogginess as the most common side effect.

    Guides updated

      February 8, 2026

      Saffron for mild-to-moderate depression — a careful yes

      What changed
      Two 2023–2024 meta-analyses found saffron (30 mg/day standardised extract) roughly comparable to first-line SSRIs for mild-to-moderate depression at 6–8 weeks.
      Why it matters
      This is a rare case where a traditional Persian remedy has genuinely credible modern evidence behind it.
      How Hakim responded
      Added a dedicated evidence section to the saffron guide, kept safety guidance for pregnancy and drug interactions, and cross-linked it to the mood and stress guides.

      Guides updated

      January 20, 2026

      Vitamin D above 2000 IU/day — humility, not enthusiasm

      What changed
      The VITAL trial's extended follow-up and 2024 endocrine-society guidance no longer support routine high-dose vitamin D for the general adult population without a documented deficiency.
      Why it matters
      Vitamin D was oversold. It matters, but mostly for people who are actually low.
      How Hakim responded
      Reframed the vitamin D notes across the aging, bone, and immunity guides — test first, supplement modestly, don't chase a number.

      Guides updated

      Hakim